Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleNasdaq· June 26, 2026
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
View original at nasdaq.comWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired (RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The workforce reduction is projected to deliver $10 million in annualised cost savings.
60% confidenceADC Therapeutics maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations.
60% confidenceDT120 ODT was generally well tolerated, with no serious adverse events or suicidality signal.
60% confidenceMerck KGaA expects to realise annual cost savings of approximately 140 million euros by the third year following the Bio-Techne deal closure.
60% confidenceThe company plans to resubmit the Cytisinicline NDA in Q4 2026, targeting a potential approval in H1 2027 if no further major issues arise.
60% confidence
Citado en estos reportajes de Via News
- Oncología en 2026: Summit gasta más de lo que ingresa mientras fármacos, IA y adquisiciones redefinen el sector →
- Oncología en otoño de 2026: tres fechas que pueden mover el sector, y las cuentas de Merck detrás de la apuesta →
- Oncología: la IA, las vacunas de ARNm y las combinaciones ADC-biespecífico avanzan, pero los datos clave llegan en las próximas semanas →
- Vacunas personalizadas de ARNm y biológicos diseñados con IA: lo que está comprobado, lo que falta y lo que revelan las cuentas de Merck →
